Companies To Watch
-
Companies To Watch: Cidara Therapeutics
8/3/2020
Cidara Therapeutics is training its novel treatment and preventative for flu and other viral infections on Covid-19.
-
Companies To Watch: Equillium
7/1/2020
Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.
-
Companies To Watch: Spring Bank Pharmaceuticals
6/1/2020
Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.
-
Companies To Watch: argenx
5/1/2020
Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.
-
Companies To Watch: Neurana
4/1/2020
This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.
-
Companies To Watch: Adaptive Phage Therapeutics
2/28/2020
Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.
-
Companies To Watch: Imago BioSciences
1/31/2020
In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.
-
Companies To Watch: Scynexis
12/30/2019
Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.
-
Companies To Watch: Obsidian Therapeutics
11/1/2019
Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.
-
Companies To Watch: eXIthera
10/1/2019
This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.